SubHero Banner
Text

Opdivo® (nivolumab) and Yervoy® (ipilimumab) – New indication

April 16, 2017 - Bristol-Myers Squibb announced the FDA approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the combination treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC).

Download PDF